BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Reddavid R, Sofia S, Chiaro P, Colli F, Trapani R, Esposito L, Solej M, Degiuli M. Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake? World J Gastroenterol 2018; 24(2): 274-289 [PMID: 29375213 DOI: 10.3748/wjg.v24.i2.274] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 26] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 Kim CH, Kim DJ, Kim W. The role of laparoscopic management in perforated gastric cancer. Ann Surg Treat Res 2021;101:151-9. [PMID: 34549038 DOI: 10.4174/astr.2021.101.3.151] [Reference Citation Analysis]
2 Reddavid R, Strignano P, Sofia S, Evangelista A, Deiro G, Cannata G, Chiaro P, Maiello F, Mineccia M, Ferrero A, Leli R, Gentilli S, Polastri R, Borghi F, Camandona M, Romagnoli R, Morino M, Degiuli M. Transhiatal distal esophagectomy for Siewert type II cardia cancer can be a treatment option in selected patients. Eur J Surg Oncol 2019;45:1943-9. [PMID: 31005469 DOI: 10.1016/j.ejso.2019.04.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Kronenfeld JP, Collier AL, Turgeon MK, Ju M, Alterio R, Wang A, Fernandez M, Porembka MR, Richter H, Lee AY, Russell MC, Merchant NB, Maker AV, Datta J. Attrition during neoadjuvant chemotherapy for gastric adenocarcinoma is associated with decreased survival: A United States Safety-Net Collaborative analysis. J Surg Oncol 2021. [PMID: 34379324 DOI: 10.1002/jso.26638] [Reference Citation Analysis]
4 Degiuli M, Reddavid R, Tomatis M, Ponti A, Morino M, Sasako M; of the Italian Gastric Cancer Study Group (IGCSG). D2 dissection improves disease-specific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian Gastric Cancer Study Group D1 versus D2 randomised controlled trial. Eur J Cancer 2021;150:10-22. [PMID: 33887514 DOI: 10.1016/j.ejca.2021.03.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Liu ZN, Wang YK, Zhang L, Jia YN, Fei S, Ying XJ, Zhang Y, Li SX, Sun Y, Li ZY, Ji JF. Comparison of tumor regression grading systems for locally advanced gastric adenocarcinoma after neoadjuvant chemotherapy. World J Gastrointest Oncol 2021; 13(12): 2161-2179 [DOI: 10.4251/wjgo.v13.i12.2161] [Reference Citation Analysis]
6 Wang L, Li W, Liu Y, Zhang C, Gao W, Gao L, Zhong WL. Clinical Efficacy and Safety of Bevacizumab, Apatinib, and Recombinant Human Endothelial Inhibitor in the Treatment of Advanced Gastric Cancer. Journal of Oncology 2022;2022:1-5. [DOI: 10.1155/2022/6189833] [Reference Citation Analysis]
7 Cheng Z, Gao S, Liang X, Lian C, Chen J, Fang C. Inhibiting PP2Acα Promotes the Malignant Phenotype of Gastric Cancer Cells through the ATM/METTL3 Axis. Biomed Res Int 2021;2021:1015293. [PMID: 34485508 DOI: 10.1155/2021/1015293] [Reference Citation Analysis]
8 Coimbra FJF, de Jesus VHF, Ribeiro HSC, Diniz AL, de Godoy AL, de Farias IC, Felismino T, Mello CAL, Almeida MF, Begnami MDFS, Dias-Neto E, Riechelmann RSP, da Costa WL Jr. Impact of ypT, ypN, and Adjuvant Therapy on Survival in Gastric Cancer Patients Treated with Perioperative Chemotherapy and Radical Surgery. Ann Surg Oncol 2019;26:3618-26. [PMID: 31222685 DOI: 10.1245/s10434-019-07454-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
9 Zhang L, Song M, Zhang F, Yuan H, Chang W, Yu G, Niu Y. Accumulation of Nicotinamide N-Methyltransferase (NNMT) in Cancer-associated Fibroblasts: A Potential Prognostic and Predictive Biomarker for Gastric Carcinoma. J Histochem Cytochem 2021;69:165-76. [PMID: 33283625 DOI: 10.1369/0022155420976590] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 da Costa WL Jr, Gu X, Farjah F, Groth SS, Burt BM, Ripley RT, Carrott PW, Massarweh NN. Staging Concordance and Guideline-Concordant Treatment for Esophageal Adenocarcinoma. Ann Thorac Surg 2021:S0003-4975(21)00095-3. [PMID: 33484675 DOI: 10.1016/j.athoracsur.2020.12.046] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Chen Y, Xiang J, Liu D, Xiao J, Xiong F, Wei K, Liu A, Chen S, Zhu Y, Meng X, Peng J. Multidisciplinary team consultation for resectable Gastric Cancer: A propensity score matching analysis. J Cancer 2021;12:1907-14. [PMID: 33753988 DOI: 10.7150/jca.53365] [Reference Citation Analysis]
12 Douridas GN, Fountoulakis A, Souglakos J, Gourtsoyianni S, Vini L, Levidou G, Liakakos T, Agalianos C, Dervenis C, Kalogeridi MA, Karavokyros I, Koumarianou A, Kountourakis P, Oikonomopoulos G, Economopoulou P, Sgouros J, Sgouros SN, Stamou K, Triantopoulou C, Zacharoulis D, Gouvas N, Xynos E. Consensus statement of the Hellenic and Cypriot Gastric Cancer Study Group on the diagnosis, staging and management of gastric cancer. Updates Surg 2020;72:1-19. [PMID: 32112342 DOI: 10.1007/s13304-020-00723-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Meng Y, Huang X, Liu J, Chen J, Bu Z, Wu G, Xie W, Jeen F, Huang L, Tian C, Mo X, Tang W. A Novel Nomogram for Individually Predicting of Vascular Invasion in Gastric Cancer. Technol Cancer Res Treat 2021;20:15330338211004924. [PMID: 33929914 DOI: 10.1177/15330338211004924] [Reference Citation Analysis]
14 Sandø AD, Fougner R, Grønbech JE, Bringeland EA. The value of restaging CT following neoadjuvant chemotherapy for resectable gastric cancer. A population-based study. World J Surg Oncol 2021;19:212. [PMID: 34256790 DOI: 10.1186/s12957-021-02313-3] [Reference Citation Analysis]
15 Xu J, Wang X, Ke Q, Liao K, Wan Y, Zhang K, Zhang G, Wang X. Combined bioinformatics technology to explore pivot genes and related clinical prognosis in the development of gastric cancer. Sci Rep 2021;11:15412. [PMID: 34326374 DOI: 10.1038/s41598-021-94291-5] [Reference Citation Analysis]
16 D'Ugo D, Agnes A, Grieco M, Biondi A, Persiani R. Global updates in the treatment of gastric cancer: a systematic review. Part 2: perioperative management, multimodal therapies, new technologies, standardization of the surgical treatment and educational aspects. Updates Surg 2020;72:355-78. [PMID: 32306277 DOI: 10.1007/s13304-020-00771-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Chen YH, Xiao J, Chen XJ, Wang HS, Liu D, Xiang J, Peng JS. Nomogram for predicting pathological complete response to neoadjuvant chemotherapy in patients with advanced gastric cancer. World J Gastroenterol 2020; 26(19): 2427-2439 [PMID: 32476803 DOI: 10.3748/wjg.v26.i19.2427] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
18 Yu JH, Wang ZZ, Fan YC, Liu MX, Xu K, Zhang N, Yao ZD, Yang H, Zhang CH, Xing JD, Cui M, Su XQ. Comparison of neoadjuvant chemotherapy followed by surgery vs. surgery alone for locally advanced gastric cancer: a meta-analysis. Chin Med J (Engl) 2021;134:1669-80. [PMID: 34397593 DOI: 10.1097/CM9.0000000000001603] [Reference Citation Analysis]
19 Sato M, Endo K, Harada A, Shijo M. A case of successful conversion surgery for gastric cancer with direct invasion to pancreatic head. J Surg Case Rep 2021;2021:rjab186. [PMID: 34025973 DOI: 10.1093/jscr/rjab186] [Reference Citation Analysis]
20 Zhou L, Li SH, Wu Y, Xin L. Establishment of a prognostic model of four genes in gastric cancer based on multiple data sets. Cancer Med 2021;10:3309-22. [PMID: 33934516 DOI: 10.1002/cam4.3654] [Reference Citation Analysis]
21 Capovilla G, Froiio C, Lang H, Berlth F, Grimminger PP. [Complete response after neoadjuvant therapy for gastric cancer: implications for surgery]. Chirurg 2021. [PMID: 34622304 DOI: 10.1007/s00104-021-01516-4] [Reference Citation Analysis]
22 Bracale U, Merola G, Pignata G, Andreuccetti J, Dolce P, Boni L, Cassinotti E, Olmi S, Uccelli M, Gualtierotti M, Ferrari G, De Martini P, Bjelović M, Gunjić D, Silvestri V, Pontecorvi E, Peltrini R, Pirozzi F, Cuccurullo D, Sciuto A, Corcione F. Laparoscopic gastrectomy for stage II and III advanced gastric cancer: long‑term follow‑up data from a Western multicenter retrospective study. Surg Endosc 2021. [PMID: 33877411 DOI: 10.1007/s00464-021-08505-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Chen Y, Liu D, Xiao J, Xiang J, Liu A, Chen S, Liu J, Hu X, Peng J. Nomogram for Predicting Survival in Advanced Gastric Cancer after Neoadjuvant Chemotherapy and Radical Surgery. Gastroenterol Res Pract 2021;2021:2923700. [PMID: 34367276 DOI: 10.1155/2021/2923700] [Reference Citation Analysis]
24 Lu H, Sun Y, Zhu Z, Xu H, Huang R, Huang B. Differentiated/undifferentiated mixed type is a prognostic factor for T2/T3 gastric cancer patients. Expert Rev Gastroenterol Hepatol 2021;15:1329-36. [PMID: 34431734 DOI: 10.1080/17474124.2021.1973430] [Reference Citation Analysis]
25 Li JQ, He D, Liang YX. Current status of extended 'D2 plus' lymphadenectomy in advanced gastric cancer. Oncol Lett 2021;21:467. [PMID: 33907577 DOI: 10.3892/ol.2021.12728] [Reference Citation Analysis]
26 Reddavid R, Dagatti S, Franco C, Puca L, Tomatis M, Corso S, Giordano S, Degiuli M. Molecularly Targeted Therapies for Gastric Cancer. State of the Art. Cancers (Basel) 2021;13:4094. [PMID: 34439248 DOI: 10.3390/cancers13164094] [Reference Citation Analysis]
27 Chen L, Chen Y, Zhang L, Xue Y, Zhang S, Li X, Song H. In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator. Pathol Oncol Res 2021;27:1609811. [PMID: 34712105 DOI: 10.3389/pore.2021.1609811] [Reference Citation Analysis]
28 Tham E, Sestito M, Markovich B, Garland-Kledzik M. Current and future imaging modalities in gastric cancer. J Surg Oncol 2022;125:1123-34. [PMID: 35481912 DOI: 10.1002/jso.26875] [Reference Citation Analysis]
29 Yu P, Zhu S, Luo Y, Li G, Pu Y, Cai B, Zhang C, Wang F. Application of Circulating Tumor Cells and Circulating Free DNA from Peripheral Blood in the Prognosis of Advanced Gastric Cancer. Journal of Oncology 2022;2022:1-9. [DOI: 10.1155/2022/9635218] [Reference Citation Analysis]
30 Li SS, Klempner SJ, Costantino CL, Parikh A, Clark JW, Wo JY, Hong TS, Mullen JT. Impact of Treatment Sequencing on Survival for Patients with Locally Advanced Gastric Cancer. Ann Surg Oncol 2021;28:2856-65. [PMID: 33393043 DOI: 10.1245/s10434-020-09248-1] [Reference Citation Analysis]
31 Beeharry MK, Zhang TQ, Liu WT, Gang ZZ. Optimization of perioperative approaches for advanced and late stages of gastric cancer: clinical proposal based on literature evidence, personal experience, and ongoing trials and research. World J Surg Oncol 2020;18:51. [PMID: 32151257 DOI: 10.1186/s12957-020-01819-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
32 Wang J, Sun Y, Zhang X, Cai H, Zhang C, Qu H, Liu L, Zhang M, Fu J, Zhang J, Wang J, Zhang G. Oxidative stress activates NORAD expression by H3K27ac and promotes oxaliplatin resistance in gastric cancer by enhancing autophagy flux via targeting the miR-433-3p. Cell Death Dis 2021;12:90. [PMID: 33462197 DOI: 10.1038/s41419-020-03368-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Bausys A, Senina V, Luksta M, Anglickiene G, Molnikaite G, Bausys B, Rybakovas A, Baltruskeviciene E, Laurinavicius A, Poskus T, Bausys R, Seinin D, Strupas K. Histologic Lymph Nodes Regression after Preoperative Chemotherapy as Prognostic Factor in Non-metastatic Advanced Gastric Adenocarcinoma. J Cancer 2021;12:1669-77. [PMID: 33613754 DOI: 10.7150/jca.49673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Seko-Nitta A, Nagatani Y, Murakami Y, Watanabe Y, Nitta N, Murata K, Takemura S, Murata S. 18F-fluorodeoxyglucose uptake in advanced gastric cancer correlates with histopathological subtypes and volume of tumor stroma. Eur J Radiol 2021;145:110048. [PMID: 34814038 DOI: 10.1016/j.ejrad.2021.110048] [Reference Citation Analysis]
35 Trastulli S, Desiderio J, Lin JX, Reim D, Zheng CH, Borghi F, Cianchi F, Norero E, Nguyen NT, Qi F, Coratti A, Cesari M, Bazzocchi F, Alimoglu O, Brower ST, Pernazza G, D'Imporzano S, Azagra JS, Zhou YB, Cao SG, Garofoli E, Mosillo C, Guerra F, Liu T, Arcuri G, González P, Staderini F, Marano A, Terrenato I, D'Andrea V, Bracarda S, Huang CM, Parisi A. Laparoscopic Compared with Open D2 Gastrectomy on Perioperative and Long-Term, Stage-Stratified Oncological Outcomes for Gastric Cancer: A Propensity Score-Matched Analysis of the IMIGASTRIC Database. Cancers (Basel) 2021;13:4526. [PMID: 34572753 DOI: 10.3390/cancers13184526] [Reference Citation Analysis]
36 Xu H, Zhang L, Miao J, Liu S, Liu H, Jia T, Zhang Q. Patterns of recurrence in adenocarcinoma of the esophagogastric junction: a retrospective study. World J Surg Oncol 2020;18:144. [PMID: 32593312 DOI: 10.1186/s12957-020-01917-5] [Reference Citation Analysis]
37 Feng C, Cheng J, Zeng X, Zhang Y, Hong N, Ye Y, Wang Y. Development and evaluation of a ceMDCT-based preoperative risk stratification model to predict disease-free survival after radical surgery in patients with gastric cancer. Abdom Radiol (NY) 2021;46:4079-89. [PMID: 33811513 DOI: 10.1007/s00261-021-03049-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]